Kailera Therapeutics appears to have set a new benchmark for biotech IPOs with an upsized $625 million offering to fund its pipeline of obesity therapies. | Kailera Therapeutics appears to have set a new benchmark for biotech IPOs with an upsized $625 million…
You are being redirected to the original discussion. Please continue if you want to read the full post.
Continue to original articleYou will be redirected in 3 seconds.